| Literature DB >> 22822375 |
Jiun-Yang Chang1,2, Chia-Ching Liaw1, Ahmed Eid Fazary1, Tsong-Long Hwang3, Ya-Ching Shen1.
Abstract
Chemical investigation of Junceella juncea has resulted in the isolation of three new briaranes designated juncenolides M-O (1-3). The structures of these compounds were determined by spectroscopic analysis including 2D-NMR (COSY, HMBC and NOESY) and HRMS. Compound 1 is a new chlorinated briarane while compound 3 contains a rare methyl ester at C-16. The anti-inflammatory activities tested on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB were evaluated.Entities:
Keywords: Junceella juncea; anti-inflammatory activity; briaranes
Mesh:
Substances:
Year: 2012 PMID: 22822375 PMCID: PMC3397442 DOI: 10.3390/md10061321
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Structures of compounds 1–3.
1H NMR Data of Compounds 1–3. δ in ppm, J in Hz.
| Position | 1 a | 2 b | 3 b |
|---|---|---|---|
| 2 | 5.37 (d, | 4.94 (overlap) | 4.86 (d, |
| 3 | 5.62 (t, | 1.74–1.78 (m) | 2.13–2.16 (m) |
| 2.46–2.50 (m) | 2.72 (t, | ||
| 4 | 6.35 (d, | 2.19–2.15 (m) | 5.91–5.94 (m) |
| 2.64 (br. d, | |||
| 6 | 6.00 (d, | 5.67 (d, | 7.06 (d, |
| 7 | 4.95 (d, | 5.26 (d, | 5.62 (d, |
| 9 | 4.71 (d, | 5.31 (d, | 5.56 (d, |
| 10 | 3.04 (d, | 3.45 (d, | 3.25 (d, |
| 12 | 1.34–1.38 (m) | 2.16–2.19 (m) | 2.18–2.23 (2H, m) |
| 2.48 (d, | 2.34–2.36 (m) | ||
| 13 | 4.96 (overlap) | 1.82–1.86 (m) | 1.80–1.87 (2H, m) |
| 1.97–1.99 (m) | |||
| 14 | 5.20 (br. s) | 4.59 (br. s) | 4.69 (br. s) |
| 15 | 1.09 (s) | 1.12 (s) | 1.03 (s) |
| 16 | 4.58 (2H, s) | 2.05 (s) | - |
| 17 | 2.26 (q, | 2.46 (q, | 2.63 (q, |
| 19 | 1.13 (d, | 1.11 (d, | 1.19 (d, |
| 20 | 2.74 (br. s) | 4.92 (s) | 4.95 (s) |
| 3.54 (br. s) | 5.05 (s) | 5.05 (s) | |
| AcO-2 | 1.95 (s) | - | 1.97 (s) |
| AcO-4 | - | - | 2.06 (s) |
| AcO-9 | 2.18 (s) | 2.20 (s) | 2.21 (s) |
| AcO-13 | 2.07 (s) | - | - |
| AcO-14 | 1.97 (s) | 1.92 (s) | 1.90 (s) |
| OMe-16 | - | - | 3.83 (s) |
a Recorded in CDCl3 at 300 MHz; b Recorded in CDCl3 at 400 MHz.
13C-NMR Data of Compounds 1–3.δ in ppm.
| Position | 1 a | 2 b | 3 b |
|---|---|---|---|
| 1 | 46.5 (s) | 46.9 (s) | 47.8 (s) |
| 2 | 74.2 (d) | 75.7 (d) | 72.1 (d) |
| 3 | 131.7 (d) | 31.3 (t) | 37.3 (t) |
| 4 | 128.1 (d) | 29.2 (t) | 67.4 (d) |
| 5 | 140.0 (s) | 144.8 (s) | 136.8 (s) |
| 6 | 126.1 (d) | 120.5 (d) | 139.1 (d) |
| 7 | 78.5 (d) | 77.8 (d) | 76.7 (d) |
| 8 | 80.8 (s) | 83.0 (s) | 82.9 (s) |
| 9 | 64.3 (d) | 71.3 (d) | 72.7 (d) |
| 10 | 35.7 (d) | 41.8 (d) | 42.6 (d) |
| 11 | 58.1 (s) | 150.8 (s) | 150.5 (s) |
| 12 | 34.3 (t) | 26.3 (t) | 29.2 (t) |
| 13 | 67.7 (d) | 26.9 (t) | 27.5 (t) |
| 14 | 73.8 (d) | 74.5 (d) | 74.0 (d) |
| 15 | 14.4 (q) | 15.4 (q) | 14.4 (q) |
| 16 | 44.7 (t) | 27.2 (q) | 166.6 (s) |
| 17 | 43.9 (d) | 42.5 (d) | 43.3 (d) |
| 18 | 175.3 (s) | 175.9 (s) | 175.3 (s) |
| 19 | 6.3 (q) | 6.5 (q) | 6.4 (q) |
| 20 | 50.2 (t) | 113.3 (t) | 113.3 (t) |
| AcO-2 | 170.2 (s) | - | 169.9 (s) |
| 20.8 (q) | 20.8 (q) | ||
| AcO-4 | - | - | 169.6 (s) |
| 21.2 (q) | |||
| AcO-9 | 170.0 (s) | 169.3 (s) | 169.2 (s) |
| 21.6 (q) | 21.7 (q) | 21.7 (q) | |
| AcO-13 | 170.0 (s) | - | - |
| 21.3 (q) | |||
| AcO-14 | 170.2 (s) | 170.4 (s) | 170.5 (s) |
| 21.0 (q) | 21.2 (q) | 21.1 (q) | |
| OMe-16 | - | - | 52.8 (q) |
a Recorded in CDCl3 at 75 MHz; b Recorded in CDCl3 at 100 MHz.
Figure 2Key 1H–1H COSY and HMBC correlations of 1–3.
Figure 3Key NOESY correlations of compounds 1–3 in molecular modeling.
Effects of compounds 1–3 on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB a.
|
|
|
|
| Inhibition (%) b | Inhibition (%) | |
|
| 7.6 ± 2.8 | 15.9 ± 5.5 |
|
| 6.7 ± 2.9 | 29.0 ± 5.6 |
|
| 27.6 ± 7.0 | 35.9 ± 7.4 |
| Genistein | 65.0 ± 5.7 | 51.6 ± 5.9 |
a Results are presented as mean ± S.E.M. (n = 3); b Percent of inhibition at 10 μg/mL.